Reference entry — not sold here. The muscle world's hyperplasia dream — building new muscle fibres, not just bigger ones — and the honest reality behind it. Three things up front: it's a protein, not a peptide; there are zero human trials of it for muscle; and the safety profile is genuinely serious
IGF-1 LR3 is a long-acting engineered version of IGF-1, prized in the muscle community for one genuinely special property — hyperplasia, the formation of new muscle fibres via satellite cells, which steroids cannot do. But the honest reality is stark: it was created as a cell-culture reagent, no human trial has ever tested it for muscle or anything else, the hyperplasia effect in humans is debated, and its safety profile — hypoglycemia, tumour-promotion risk, organ overgrowth — is serious. Thrilling mechanism; unproven and genuinely risky product. Banned in sport.
- Everywhere — not approved for muscle, performance or anti-aging. Native IGF-1 (mecasermin / Increlex) is FDA- and EMA-approved for pediatric severe primary IGF-1 deficiency only; IGF-1 LR3 is not separately authorised for anything therapeutic — it's a research / cell-culture reagent sold gray-market for bodybuilding. - ⚠ Sport: WADA-prohibited at all times — Section S2 (Peptide Hormones, Growth
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
the hyperplasia idea is real and genuinely exciting — but it's proven in a Petri dish and lab animals, and the exact molecule you'd buy was designed to grow cells in that dish, not muscle in you. Zero human trials, a hypoglycemia risk that has put people in hospital, and — because it's built to evade the very system that normally keeps IGF-1 in check — a cancer concern that is essentially unstudied over the long term. Respect the mechanism; don't trust the vial.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.